Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature SkinNCT07774260

Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin

A study testing Deep Microspicule Cream in people with Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin, run by Chung Shan Medical University at 1 site in Taiwan.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts

Official record

Search all trials

Trial summary

This study is a single-center, prospective, split-face self-controlled pilot trial designed to evaluate the anti-aging and whitening efficacy of the "Deep Microspicule Cream" (containing patented crystal microspicules encapsulating Penghu seaweed extract) on mature skin. Read more about this study

Who is it for?: Ages 40 to 65 yearsHealthy volunteers can take part
Conditions the study is for: Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin
What is being tested?: Deep Microspicule Cream
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 10 participants
Where: 1 siteTaiwan
Study dates: 1 Sep 2026to 30 Oct 2026
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 65 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Healthy male or female participants aged 40-65 years.
Presence of at least one facial aging or hyperpigmentation feature (e.g., eye area sagging, eye bags, crow's feet, fine lines, freckles, sun spots, uneven skin tone, or dullness).
Willing to complete 3 study visits within 4 weeks, comply with instrumental measurements, and maintain product logs.
Willing to sign the Informed Consent Form (ICF).

Who cannot join

Received facial aesthetic treatments (e.g., lasers, chemical peels, microneedling, energy-based therapies) within 4 weeks.
Used topical/oral retinoic acid or strong whitening creams (e.g., high-concentration hydroquinone) within 4 weeks.
Severe sensitive skin, active atopic dermatitis, or obvious facial skin lesions/infections.
Facial salon or exfoliation treatments more frequent than once every 2 weeks.
Known allergy to seaweed-derived ingredients or product preservative systems.
Uncontrolled systemic diseases (e.g., diabetes, kidney/liver/cardiovascular diseases, severe infections, endocrine disorders, or cancer).
Pregnant, lactating, or planning to become pregnant.
Deemed unsuitable for participation by the investigator.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

You-Cheng Mr Shen, Ph.D. contact

886-4-24730022 ext. 12107

youcheng@csmu.edu.tw

Taiwan1 site

Chung Shan Medical University
Taichung
You-Cheng Mr Shen, Ph.D., 886-4-24730022 ext. 12107, youcheng@csmu.edu.tw

Other trials in Taiwan

About this study

Read the detailed description

This study is a single-center, prospective, split-face self-controlled pilot trial.

10 healthy participants aged 40-65 who present signs of skin aging or hyperpigmentation will be enrolled.

Intervention Side (Active): Participants will apply a green-bean-sized amount of Deep Microspicule Cream on the assigned side, gently massaging to let the microspicules roll on the skin, followed by the application of Deep Essence to dissolve the microspicules.

Control Side: Participants will apply Deep Essence only. The applications are performed 3 times per week at bedtime. Clinical evaluations and instrument measurements are scheduled at Day 0 (baseline), Day 14, and Day 28. On assessment days, participants must cleanse their faces and rest in a controlled environment for 25-30 minutes without applying any cosmetics before undergoing non-invasive skin assessments.

Conditions: Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin
Being tested: Deep Microspicule Cream
Keywords: Microspicule, Anti-aging, Whitening

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Deep Microspicule CreamOther
"A topical cream (Deep Microspicule Cream) utilizing patented crystal microspicule technology to encapsulate Penghu seaweed extracts (including Caulerpa microphysa, Sargassum hemiphyllum, and Botryocladia leptopoda). These ingredients possess potential anti-inflammatory, antioxidant, and collagen-promoting properties.
Participants will apply a green-bean-sized amount of the cream strictly to the randomly assigned intervention side of the face (left or right). The cream should be massaged gently on the designated side to allow the microspicules to roll on the skin surface (avoiding harsh rubbing). This application regimen is to be performed three times per week (Mondays, Wednesdays, and Saturdays) at night after facial cleansing, for a total duration of 28 days."

Study groups in NCT07774260
Study group	Role	What they receive
Split-Face Control Group	Experimental	"All 10 participants in this group will undergo two different skincare regimens on randomly assigned sides of the face (left or right) for a duration of 28 days. On the designated intervention side, participants will apply a green-bean-sized amount of Deep Microspicule Cream and gently massage, followed by the application of Deep Essence to dissolve the microspicules. On the opposite control side, participants will apply Deep Essence only as a within-subject control. Both regimens are to be applied three times per week (Mondays, Wednesdays, and Saturdays) at night after cleansing. Receives: Other: Deep Microspicule Cream

What is being measured

The primary outcome is the main question the study is designed to answer.

Skin Hydration,Transepidermal Water Loss (TEWL),Skin Elasticity,Erythema Index,Skin Color
"Using the Cutometer® MPA 580 to sequentially measure skin hydration, transepidermal water loss (TEWL), skin elasticity, erythema index, and skin color."
Measured: Baseline (Day 0), Day 14, Day 28

Secondary outcomes (1)

skin texture smoothness, visual radiance (glossiness), and skin firmness
"Subjective evaluation of skin improvement including skin feel (texture smoothness), visual radiance (glossiness), and skin firmness, assessed via a 7-point Likert scale (ranging from 1 = very dissatisfied to 7 = very satisfied)
.
Measured: Baseline (Day 0), Day 14, Day 28

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Sep 202630 Oct 2026

First posted19 Aug 2026
Study start1 Sep 2026 (estimated)
Primary completion30 Oct 2026 (estimated)
Study completion30 Oct 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (11)Papers the sponsor has linked to this study.
Other trials for Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature SkinStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 10 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07774260
Sponsor's protocol ID: CS1-26029
Status last verified: Aug 2026
First submitted: 14 Aug 2026
Last updated: 19 Aug 2026
Results posted: No
FDA-regulated drug: No
FDA-regulated device: No

Publications

Nawaz T, Shin J, Shieh M, Yoo JY. A Split-Face Micro-Needling Study to Evaluate the Efficacy and Consumer Perception of a Novel Moisturization Agent. J Cosmet Dermatol. 2025 Mar;24(3):e70109. doi: 10.1111/jocd.70109.
PubMed 40099382
Friedman O. Changes associated with the aging face. Facial Plast Surg Clin North Am. 2005 Aug;13(3):371-80. doi: 10.1016/j.fsc.2005.04.004.
PubMed 16085282
Zouboulis CC, Makrantonaki E. Clinical aspects and molecular diagnostics of skin aging. Clin Dermatol. 2011 Jan-Feb;29(1):3-14. doi: 10.1016/j.clindermatol.2010.07.001.
PubMed 21146726
2. M. B. Ariede, T. M. Candido, A. L. M. Jacome, M. V. R. Velasco, J. C. M. de Carvalho, and A. R. Baby, Cosmetic attributes of algae - A review. Algal Research 2017, 25, 483-487.
Farage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. Int J Cosmet Sci. 2008 Apr;30(2):87-95. doi: 10.1111/j.1468-2494.2007.00415.x.
PubMed 18377617
Lu KY, Cheng LC, Hung ZC, Chen ZY, Wang CW, Hou HH. The Ethyl Acetate Extract of Caulerpa microphysa Promotes Collagen Homeostasis and Inhibits Inflammation in the Skin. Curr Issues Mol Biol. 2024 Mar 21;46(3):2701-2712. doi: 10.3390/cimb46030170.
PubMed 38534786
Rocha DHA, Pinto DCGA, Silva AMS. Macroalgae Specialized Metabolites: Evidence for Their Anti-Inflammatory Health Benefits. Mar Drugs. 2022 Dec 19;20(12):789. doi: 10.3390/md20120789.
PubMed 36547936
Thomas R, Wang W, Su DM. Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immun Ageing. 2020 Jan 20;17:2. doi: 10.1186/s12979-020-0173-8. eCollection 2020.
PubMed 31988649
Bocheva GS, Slominski RM, Slominski AT. Immunological Aspects of Skin Aging in Atopic Dermatitis. Int J Mol Sci. 2021 May 27;22(11):5729. doi: 10.3390/ijms22115729.
PubMed 34072076
Fitsiou E, Pulido T, Campisi J, Alimirah F, Demaria M. Cellular Senescence and the Senescence-Associated Secretory Phenotype as Drivers of Skin Photoaging. J Invest Dermatol. 2021 Apr;141(4S):1119-1126. doi: 10.1016/j.jid.2020.09.031. Epub 2020 Dec 19.
PubMed 33349436
Goldberg EL, Dixit VD. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev. 2015 May;265(1):63-74. doi: 10.1111/imr.12295.
PubMed 25879284

Study at a glance

From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin
ClinicalTrials.gov ID: NCT07774260
Acronym / sponsor ID: CS1-26029
Conditions: Efficacy Validation of Deep Microspicule Cream for Anti-aging and Whitening on Mature Skin
Keywords: Microspicule, Anti-aging, Whitening
Study type: Interventional
Recruitment status: Not yet recruiting
Enrolment: 10 participants (estimated)
Lead sponsor: Chung Shan Medical UniversityUniversity, hospital or other
Study start: 1 Sep 2026 (estimated)
Primary completion: 30 Oct 2026 (estimated)
Study completion: 30 Oct 2026 (estimated)
First posted: 19 Aug 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This study is a single-center, prospective, split-face self-controlled pilot trial.

10 healthy participants aged 40-65 who present signs of skin aging or hyperpigmentation will be enrolled.

Study design

Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
Split-Face Control Group	Experimental	Other: Deep Microspicule Cream"All 10 participants in this group will undergo two different skincare regimens on randomly assigned sides of the face (left or right) for a duration of 28 days. On the designated intervention side, participants will apply a green-bean-sized amount of Deep Microspicule Cream and gently massage, followed by the application of Deep Essence to dissolve the microspicules. On the opposite control side, participants will apply Deep Essence only as a within-subject control. Both regimens are to be applied three times per week (Mondays, Wednesdays, and Saturdays) at night after cleansing.

Who may qualify

Ages: 40 to 65 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Healthy male or female participants aged 40-65 years.
Presence of at least one facial aging or hyperpigmentation feature (e.g., eye area sagging, eye bags, crow's feet, fine lines, freckles, sun spots, uneven skin tone, or dullness).
Willing to complete 3 study visits within 4 weeks, comply with instrumental measurements, and maintain product logs.
Willing to sign the Informed Consent Form (ICF).

Key exclusion criteria (8 listed)

Received facial aesthetic treatments (e.g., lasers, chemical peels, microneedling, energy-based therapies) within 4 weeks.
Used topical/oral retinoic acid or strong whitening creams (e.g., high-concentration hydroquinone) within 4 weeks.
Severe sensitive skin, active atopic dermatitis, or obvious facial skin lesions/infections.
Facial salon or exfoliation treatments more frequent than once every 2 weeks.
Known allergy to seaweed-derived ingredients or product preservative systems.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Deep Microspicule Cream"A topical cream (Deep Microspicule Cream) utilizing patented crystal microspicule technology to encapsulate Penghu seaweed extracts (including Caulerpa microphysa, Sargassum hemiphyllum, and Botryocladia leptopoda). These ingredients possess potential anti-inflammatory, antioxidant, and collagen-promoting properties. Participants will apply a green-bean-sized amount of the cream strictly to the randomly assigned intervention side of the face (left or right). The cream should be massaged gently on the designated side to allow the microspicules to roll on the skin surface (avoiding harsh rubbing). This application regimen is to be performed three times per week (Mondays, Wednesdays, and Saturdays) at night after facial cleansing, for a total duration of 28 days."	Other	Split-Face Control Group

Primary outcome

Skin Hydration,Transepidermal Water Loss (TEWL),Skin Elasticity,Erythema Index,Skin Color
Time frame: Baseline (Day 0), Day 14, Day 28
"Using the Cutometer® MPA 580 to sequentially measure skin hydration, transepidermal water loss (TEWL), skin elasticity, erythema index, and skin color."

1 secondary outcome

skin texture smoothness, visual radiance (glossiness), and skin firmness
Time frame: Baseline (Day 0), Day 14, Day 28

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
Background: PubMed 40099382Nawaz T, Shin J, Shieh M, Yoo JY. A Split-Face Micro-Needling Study to Evaluate the Efficacy and Consumer Perception of a Novel Moisturization Agent. J Cosmet Dermatol. 2025 Mar;24(3):e70109. doi: 10.1111/jocd.70109.
Background: PubMed 16085282Friedman O. Changes associated with the aging face. Facial Plast Surg Clin North Am. 2005 Aug;13(3):371-80. doi: 10.1016/j.fsc.2005.04.004.
Background: PubMed 21146726Zouboulis CC, Makrantonaki E. Clinical aspects and molecular diagnostics of skin aging. Clin Dermatol. 2011 Jan-Feb;29(1):3-14. doi: 10.1016/j.clindermatol.2010.07.001.
Background2. M. B. Ariede, T. M. Candido, A. L. M. Jacome, M. V. R. Velasco, J. C. M. de Carvalho, and A. R. Baby, Cosmetic attributes of algae - A review. Algal Research 2017, 25, 483-487.
Background: PubMed 18377617Farage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. Int J Cosmet Sci. 2008 Apr;30(2):87-95. doi: 10.1111/j.1468-2494.2007.00415.x.
Background: PubMed 38534786Lu KY, Cheng LC, Hung ZC, Chen ZY, Wang CW, Hou HH. The Ethyl Acetate Extract of Caulerpa microphysa Promotes Collagen Homeostasis and Inhibits Inflammation in the Skin. Curr Issues Mol Biol. 2024 Mar 21;46(3):2701-2712. doi: 10.3390/cimb46030170.
Background: PubMed 36547936Rocha DHA, Pinto DCGA, Silva AMS. Macroalgae Specialized Metabolites: Evidence for Their Anti-Inflammatory Health Benefits. Mar Drugs. 2022 Dec 19;20(12):789. doi: 10.3390/md20120789.
Background: PubMed 31988649Thomas R, Wang W, Su DM. Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immun Ageing. 2020 Jan 20;17:2. doi: 10.1186/s12979-020-0173-8. eCollection 2020.
Background: PubMed 34072076Bocheva GS, Slominski RM, Slominski AT. Immunological Aspects of Skin Aging in Atopic Dermatitis. Int J Mol Sci. 2021 May 27;22(11):5729. doi: 10.3390/ijms22115729.
Background: PubMed 33349436Fitsiou E, Pulido T, Campisi J, Alimirah F, Demaria M. Cellular Senescence and the Senescence-Associated Secretory Phenotype as Drivers of Skin Photoaging. J Invest Dermatol. 2021 Apr;141(4S):1119-1126. doi: 10.1016/j.jid.2020.09.031. Epub 2020 Dec 19.
Background: PubMed 25879284Goldberg EL, Dixit VD. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev. 2015 May;265(1):63-74. doi: 10.1111/imr.12295.

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

You-Cheng Mr Shen, Ph.D. contact

886-4-24730022 ext. 12107

youcheng@csmu.edu.tw

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact You-Cheng Mr Shen, Ph.D. (886-4-24730022 ext. 12107, youcheng@csmu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Skin Hydration,Transepidermal Water Loss (TEWL),Skin Elasticity,Erythema Index,Skin Color (time frame: Baseline (Day 0), Day 14, Day 28). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07774260, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.